Navigating FDA Risks in Life Sciences M&A: A Practical Diligence Guide
This Briefing is brought to you by AHLA’s Business Law and Governance Practice Group.
- May 28, 2026
- Vinal Patel , Katten Muchin Rosenman LLP
- Kate Hardey , Katten Muchin Rosenman LLP
Counsel advising acquirers in pharmaceutical, biotechnology, and medical device transactions must assess a target’s compliance with Food and Drug Administration (FDA) requirements in granular detail as a fundamental determinant of enterprise value, deal structure, and post-closing liability exposure. Hidden liabilities may erode transaction value, give rise to indemnification claims, or, in the most serious cases, prevent the lawful marketing of a core commercial asset altogether.
ARTICLE TAGS
You must be logged in to access this content.